# A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

> **NCT00786669** · PHASE1 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 13 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Temozolomide
- **DRUG:** Vincristine
- **DRUG:** Irinotecan
- **DRUG:** Cefixime

## Key facts

- **NCT ID:** NCT00786669
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00786669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00786669, "A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00786669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*